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Abstract
Significance: The understanding of physiological and pathological processes involving protein oxidation, par-
ticularly under conditions of aging and oxidative stress, can be aided by proteomic identification of proteins that
accumulate oxidative post-translational modifications only if these detected modifications are connected to
functional consequences. The modification of tyrosine (Tyr) residues can elicit significant changes in protein
structure and function, which, in some cases, may contribute to biological aging and age-related pathologies,
such as atherosclerosis, neurodegeneration, and cataracts. Recent Advances: Studies characterizing proteins in
which Tyr has been modified to 3-nitrotyrosine, 3,4-dihydroxyphenylalanine, 3,3¢-dityrosine and other cross-
links, or 3-chlorotyrosine are reviewed, with an emphasis on structural and functional consequences. Critical
Issues: Distinguishing between inconsequential modifications and functionally significant ones requires careful
biochemical and biophysical analysis of target proteins, as well as innovative methods for isolating the effects of
the multiple modifications that often occur under oxidizing conditions. Future Directions: The labor-intensive
task of isolating and characterizing individual modified proteins must continue, especially given the expanding
list of known modifications. Emerging approaches, such as genetic and metabolic incorporation of unnatural
amino acids, hold promise for additional focused studies of this kind. Antioxid. Redox Signal. 17, 1571–1579.
Introduction
Various oxidative post-translational modifications (PTMs)of proteins accumulate in cells during aging and disease,
particularly age-related diseases such as atherosclerosis, cat-
aracts, type 2 diabetes, and neurodegenerative diseases. Such
modifications can alter protein structure and function by
inducing conformational changes, partial or complete un-
folding, cross-linking, and/or aggregation, or by modifying
enzyme active sites, phosphorylation sites, or binding sites.
These modifications can lead to either gain or loss of function
and may serve physiological/regulatory purposes or con-
tribute to (or at least accompany) pathogenesis (see Refs. 26,
33, 42 and references cited therein).
Modifications of tyrosine
Protein tyrosine (Tyr) residues are susceptible to an array
of oxidative and nitrative modifications (Fig. 1), including
the formation of 3-nitrotyrosine (3NY), which may be reduced
to 3-aminotyrosine (1, 40); 3,4-dihydroxyphenylalanine
(DOPA); 3,3¢-dityrosine (DiY); 3-chlorotyrosine (3ClY);
3,5-dichlorotyrosine (DiClY); as well as brominated and
iodinated forms (6, 33, 42). Further oxidation can convert
DOPA to dopaquinone (DQ) or 3-aminotyrosine to the qui-
none imine, representing acceptors for additions. Subse-
quently, protein-bound conjugate DQ and quinone imine may
propagate oxidative damage to DNA and lipids, as well as
other proteins (28). Additionally, ortho-tyrosine (2-hydro-
xyphenylalanine, o-Tyr) and meta-tyrosine (3-hydro-
xyphenylalanine, m-Tyr) are products of reaction between
hydroxyl radicals (or their metal-bound equivalents) and Phe
(Refs. 26, 33, 42 and references cited therein). While mostly
nonenzymatic, all of these modifications can preferentially
accumulate on specific proteins, as well as specific residues
within those proteins (1, 26, 33).
Consequences of modification
In many cases, oxidation targets proteins for degradation,
perhaps due to the increased surface hydrophobicity that
results from unfolding or misfolding (8, 11, 33, 42). However,
after extensive oxidative modification and/or when cross-
links and aggregates form, proteins can become resistant to
and even inhibit proteolysis, leading to pathological accu-
mulation and deposition (8, 11, 42). Proteolysis by both
proteasomal and lysosomal pathways also tends to decline
with aging and certain disease states, which may further
contribute to cellular senescence and to pathologies charac-
terized by protein deposition, such as atherosclerosis, cata-
ract, macular degeneration, rheumatoid arthritis, and
neurodegenerative diseases like Alzheimer’s disease (AD),
Parkinson’s disease (PD), and amyotrophic lateral sclerosis
(ALS) (8, 11, 18, 33, 42).
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The introduction of modified residues within proteins and
any associated structural changes can create neo-epitopes for
antibody recognition, and cross-reactivity with unmodified
self-proteins can induce autoimmune disorders. This is par-
ticularly relevant for modified proteins that are absent during
early development but accumulate with age (1, 26, 33).
In addition to these general consequences for proteins,
oxidation can have specific effects on the function of a par-
ticular protein. For example, it can modify an active site, block
a phosphorylation site, or disrupt a binding site for substrates,
cofactors, or partner proteins. If a particular modification is
reversible through repair or eliminated through protein
turnover, it may serve a regulatory function and/or partici-
pate in cellular signaling pathways (Refs. 1, 26, 33, and ref-
erences cited therein).
Importance of site specificity
While overall levels of a particular Tyr modification (e.g.,
protein-bound 3NY or DOPA) may or may not be measurably
elevated in a particular tissue or cell sample, specific proteins
may carry significant levels of such modifications (26, 33).
When these proteins are of low abundance, the absolute
quantity of the modification will not contribute significantly
FIG. 1. Endogenous post-translational modifications of protein-bound Tyr. EPO, eosinophil peroxidase; MPO, myelo-
peroxidase; TPO, thyroid peroxidase.
1572 FEENEY AND SCHÖNEICH
to the overall yield in the sample. Nevertheless, the modifi-
cation may be physiologically important. For this reason,
many proteomic studies have been undertaken to identify
long lists of Tyr-modified proteins. However, the focus of the
present review will be on progress made in characterizing the
effects of specific protein modifications on structure, function,
aggregation, and pathogenesis, with an emphasis on impli-
cations for aging. We will predominantly review studies
published over the last 5 years.
3-Nitrotyrosine
Formation and significance
3-Nitrotyrosine (3NY) is the most commonly measured Tyr
oxidation product, due to its relative chemical stability, the
availability of anti-3NY antibodies, and its status as a marker
of nitric oxide (NO)-dependent protein modifications. 3NY is
generated by several pathways, including reactions of per-
oxynitrite (ONOO - ) or nitrogen dioxide (NO2), and catalysis
by heme-containing proteins (26, 33). The nitration of Tyr can
lead to conformational changes, unfolding, aggregation, im-
munogenicity, and/or partial or total inactivation of a target
protein, although in some cases gain of function has been
observed. These consequences may be attributed to changes
in steric requirements, electrostatics, pKa of amino acid side
chains, and/or surface hydrophobicity. Going beyond tables
of proteomic identifications, there have been significant de-
velopments in the study of specific protein nitration sites and
their effects on structure and function. The possibility of 3NY
as a signaling moiety has also been proposed, and evidence
has been presented for pathological roles of 3NY-containing
proteins. For a comprehensive review, see Ref. 26 and refer-
ences cited therein.
Inactivation of MnSOD by nitration
of Tyr-34 in the active site
The activity of human manganese superoxide dismutase
(MnSOD), which protects cells from damage by scavenging
superoxide, is largely inhibited by nitration at Tyr-34 in the
active site, and this modification has been observed in aging,
ALS, AD, PD, and diabetes, among others (20, 26). Quint et al.
(32) determined the crystal structures of both native and ni-
trated enzyme in order to investigate the mechanism of this
inactivation (Fig. 2). Treatment with peroxynitrite gave 75%
yield of 3NY-34 and reduced enzymatic activity to 20% – 5%
compared to that of the wild-type enzyme. Although mass
spectrometry identified additional modification sites, 3NY-34
was the only modification present in the crystal structure.
While no significant conformational changes were evident
upon nitration, enzyme inhibition was attributed to steric
interference with substrate binding and changes in the hy-
drogen bonding network. Electrostatic changes due to the
lower phenolic pKa of 3NY relative to Tyr may also alter the
finely-tuned redox potential in the active site and/or cause
repulsion of the substrate, O2
 - , although this hypothesis was
not tested. The pKa of 3NY-34 in MnSOD is expected to be
similar to that measured spectroscopically for 3NY-34 of the
bacterial iron superoxide dismutase enzyme (FeSOD), which
is 7.95, or approximately two units lower than that of Tyr (Ref.
32 and references cited therein). In this protein environment,
this value is higher than the pKa * 7.2 measured for 3NY in
other peptides and proteins and in its free form (40, 46).
In order to isolate 3NY-34 from all other modifications that
can occur with oxidizing agents, Neumann et al. (25) used a
genetic approach for site-specific incorporation of the unnat-
ural amino acid 3NY at position 34 in recombinant rat mito-
chondrial MnSOD. Upon quantitative formation of this
nitrated mutant, the enzyme showed 97% decrease in activity.
Nitration disrupts catalysis by GAPDH
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a
crucial protein for cellular metabolism and energy, is a com-
mon entry on proteomic lists of nitrated proteins, including
studies of aging (17) and AD (43), likely due to its role as a
sensor of NO (27). In a mechanistic study, Palamalai et al. (27)
recently determined that in vitro nitration of Tyr-311 and Tyr-
317 in rabbit GAPDH by tetranitromethane resulted in loss of
binding to NAD + , thereby destroying all catalytic activity of
the enzyme. Computational analysis of the X-ray crystal
structure predicted that these nitration sites are located very
close to both the catalytic cysteine residue and the NAD +
binding site (Fig. 3). Furthermore, in silico nitration resulted
in an even shorter predicted distance (1.4 Å) between 3NY-317
and NAD + , such that significant steric interference may
FIG. 2. Active site of native (a)
and nitrated (b) human MnSOD,
shown with Mn and its ligands,
His-26, Tyr-34, His-74, Asp-159,
and His-163. Image derived from
crystal structures stored in the
Protein Data Bank (32); accession
codes 2ADQ for native and 2ADP
for nitrated. Figure generated us-
ing Protein Workshop (22).
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occur. Alternatively, the movement of this residue at the base
of an a-helix may disrupt this secondary structure. In fact,
circular dichroism shows some loss of secondary structure
following in vitro nitration.
DOPA, DQ, and Tyr-Mediated Cross-Links
DOPA and DQ
Hydroxyl radicals can convert Tyr to DOPA (14), and site-
specificity for this reaction can be facilitated by redox-active
transition metals bound to proteins or by localized sources of
hydroxyl radicals, such as mitochondria (23, 48). Through
reversible oxidation to dopaqinone (DQ), DOPA is part of a
redox cycle capable of regenerating the reduced state of
redox-active transition metals, particularly iron and copper,
and of reducing metalloproteins (9, 12, 14). This phenomenon
can perpetuate oxidative insult but also presents an oppor-
tunity for putative signaling functions, such as triggering
antioxidant defenses (23). Protein-bound DOPA can also
serve a protective role by scavenging radicals and chelating
metals, although the latter function can alternatively direct
oxidative damage to specific protein sites (23, 24, 41).
DOPA and DQ can also be formed enzymatically by ty-
rosinase or tyrosine hydroxylase (28). In addition, DOPA may
be incorporated during protein synthesis when free DOPA is
available to compete with Tyr, such as in levodopa-treated PD
patients (10).
Conjugate addition
DQ and the related quinone imine (e.g., an oxidation product
of 3-aminotyrosine) can serve as conjugate acceptors for nu-
cleophilic groups on other amino acid side chains to generate
protein cross-links (28). Protein aggregates may result that are
resistant to proteolysis and can contribute to protein deposi-
tion/plaque formation in aging and various disease states (8,
11). Conversely, such cross-links can perform important func-
tions. For example, the cofactor lysine tyrosylquinone is formed
by the intramolecular addition of Lys-314 to the DQ moiety
derived from Tyr-349 in lysyl oxidase (44).
3,3 ¢-Dityrosine
Another route to Tyr-mediated protein cross-links involves
the combination of two tyrosyl radicals to form 3,3¢-dityrosine
(DiY) (15, 42). Various pathways to the formation of tyrosyl
radicals exist, mediated by hydroxyl radicals, peroxynitrite-
derived species, peroxyl radicals, redox-active metals, c-
radiolysis, UV irradiation, heme, or hemeperoxidase enzymes
(3, 15, 42). In the hydrophobic region of biological mem-
branes, lipid-derived radicals can also play an intermediary
role (3). Specificity may arise due to conformational require-
ments for the interaction of Tyr residues. DiY modification
leads to selective proteolysis, and the released DiY is a stable
and useful biomarker for oxidative stress, for example, as
excreted in urine (15).
Although not as widely studied as 3NY, these other mod-
ifications have been linked to atherosclerosis (12), cataracts
(13, 21), levodopa therapy for PD (10), and lysosomal dys-
function (10, 11). Some proteomic studies of DOPA, for ex-
ample, have been published (19, 48), but here we will focus on
recent mechanistic studies.
Age-related cataracts
The formation of age-related cataracts in humans is asso-
ciated with up to 15-fold increases in protein-bound DOPA, as
well as elevated levels of DiY and other protein-bound amino
acid hydroxylation products, which can contribute to the
protein cross-linking and browning that characterize cata-
ractous lenses (13). DOPA and DiY formation may result from
both Fenton-type, hydroxyl-radical chemistry (13), and reac-
tions photosensitized by protein-bound tryptophan (Trp)
metabolites (21). The free Trp metabolites kynurenine, 3-
hydroxykynurenine, 3-hydroxykynurenine-O-b-D-glucoside,
4-(2-aminophenyl)-4-oxobutanoic acid, and 4-(2-amino-3-
hydroxyphenyl)-4-oxobutanoic acid serve as filters for UVA
light, as they absorb with high efficiency but are poor sensi-
tizers for the formation of singlet oxygen or radical species.
However, with aging, they become increasingly bound to lens
proteins, either covalently or noncovalently (Fig. 4). Such
protein-filter adducts accumulate in the lens nucleus, due at
least in part to a diffusional barrier that develops at middle
age. In this state, these compounds may lose their protective
function and instead promote direct and indirect photooxi-
dation of proteins, including generation of DOPA and DiY. At
the same time, the pool of free, protective filter compounds is
depleted, leaving the aging lens more susceptible to photo-
chemical damage (21).
When tested in vitro with soluble bovine lens proteins (21),
all but one of these protein-Trp metabolite adducts led to in-
creased peroxide formation (primarily hydrogen peroxide) in a
process that is sensitive to D2O (increased yield) and azide
(decreased yield), indicating the involvement of singlet oxygen.
However, the levels of DOPA and DiY were metabolite de-
pendent and insensitive to D2O. In addition, DOPA formation
was independent of illumination and atmospheric oxygen. The
authors postulated at least two reaction pathways to account
FIG. 3. Nitration sites of rabbit muscle GAPDH, Tyr-311
and Tyr-317, and their proximity to Cys-149 and NAD1 in
the active site. Image derived from the crystal structure
stored in the Protein Data Bank (7); accession code 1J0X.
Figure generated using Protein Workshop (22).
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for these differences: 1) the photosensitized formation of sin-
glet oxygen, and 2) the auto-oxidation of the o-aminophenol
moiety in 3-hydroxykynurenine or its metabolite, 4-(2-amino-
3-hydroxyphenyl)-4-oxobutanoic acid, which generates su-
peroxide. Furthermore, in the light-dependent pathway, the
excited states of the filter compounds appear to have compet-
ing energy transfer pathways, either to oxygen or to protein-
bound Tyr.
Regardless of the pathway, these phenomena generated
covalent, nondisulfide protein cross-links and may also con-
tribute to lens browning, two characteristic features of age-
related nuclear cataracts (13, 21). The DOPA levels in the Trp
metabolite study (21) were similar to those found in human
type IV nigrescent cataract lenses, while DiY levels were much
higher in the model system than in the cataract lenses. Cross-
links observed by reducing SDS-PAGE may be due to DiY and/
or reaction of nucleophilic side chains with the protein-bound
oxidation products of DOPA (i.e., DQ) or the o-aminophenol
moiety of 3-hydroxykynurenine or 4-(2-amino-3-hydroxyphenyl)-
4-oxobutanoic acid (i.e., o-quinone imine).
Lysosomal accumulation
Using metabolic incorporation of DOPA into proteins,
Dunlop et al. (11) showed that such proteins form auto-
fluorescent, SDS-stable, proteolysis-resistant aggregates in J774
murine macrophages, similar to the ‘‘aging pigment’’ lipofuscin
or its disease-related counterpart, ceroid. This aggregation is
consistent with the ability of DOPA to oxidize to DQ and react
with nucleophiles, such as cysteine residues, to form cross-
links. The perinuclear punctate pattern of fluorescence and
upregulation of the lysosomal proteases cathepsins B and L
indicate accumulation of these aggregates in lysosomes. Ly-
sosomes are rich in transition metals due to their role in au-
tophagic degradation of metal-containing proteins, and DOPA
redox cycling can continually regenerate these reactive species
to fuel oxidative damage to the lysosomal membrane, setting
off a lysosomal pathway to apoptosis, as illustrated in Figure 5
(see Ref. 18 for a review). Indeed, in a subsequent study (10),
the authors repeated this result in THP1 human monocytes and
used a variety of fluorescent staining/flow cytometry ap-
proaches to demonstrate lysosomal membrane permeabiliza-
tion, depolarization of mitochondrial membranes, decreased
mitochondrial cytochrome c levels, and increased apoptosis
(measured as phosphatidylserine externalization by Annexin
V-FITC, cellular DNA content by propidium iodide, and DNA
fragmentation by TUNEL). Lysosomal membrane permeabili-
zation occurred even in the presence of a pan-caspase inhibitor,
demonstrating that it is not caused by an early release of cas-
pases and thus indicating that it is the trigger for the apoptotic
event. In the absence of the inhibitor, Western blots showed the
cleavage of pro-caspase 3 to its active form, which is a key step
that commits cells to apoptosis, and the resulting increase in
activity was measured using a fluorigenic substrate. Lysosomal
membrane permeabilization was also replicated in SH-SY5Y
human neuroblastoma cells and MRC5 human lung fibroblasts.
Similar experiments with o-Tyr, m-Tyr, Tyr, and D-DOPA (a
negative control for protein incorporation) showed that these
effects are unique to protein-bound DOPA (10, 11). While o-Tyr
did induce lower levels of apoptosis than DOPA, as well as
lower levels of caspase 3 activation, it did not aggregate or
accumulate, indicating a separate apoptotic pathway (10).
By specifically incorporating DOPA into cellular proteins
in vitro, the study just described isolates this protein modifi-
cation from other possible consequences of oxidative stress
and defines the subsequent pathway to apoptosis. It also
mimics long-term levodopa treatment of PD patients, for
whom protein incorporation has been observed (10), and the
apoptotic events observed may contribute to the suspected
neurotoxicity of this treatment regimen. The lysosome-
mediated apoptotic pathway may be particularly relevant for
neurons and other post-mitotic cells that are more prone to
accumulation of proteolysis-resistant proteins (10). Even
without apoptotic events, the accumulation of nondegradable
proteins or lipofuscin in lysosomes can lead to mitochondrial
dysfunction, a phenomenon observed in long-lived post-
mitotic senescent cells that may contribute to aging (18).
It should also be noted that sites of metabolic DOPA in-
corporation could very well be different from those sites al-
tered by ROS in vivo. Perhaps this study is a better indication
of events occurring in large-scale oxidative stress events [in-
deed, aggregation of DOPA-containing proteins occurs only
FIG. 4. Trp metabolites can form covalent or noncovalent associations with proteins to become photosensitizers for
protein oxidation. Figure based on information from Ref. 21.
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when this oxidized amino acid is incorporated in larger
amounts (11)], but not of localized effects that may result from
highly specific redox events, such as the metal-catalyzed ox-
idation of Tyr in an enzyme’s active site. Complementary
proteomic studies could identify whether there are common
sites for metabolic incorporation versus oxidative damage,
and if any of these sites may be functionally significant, es-
pecially at lower levels of oxidative insult. Such proteomic
studies and corresponding structural and functional studies
for DOPA are currently lacking in the field.
3-Chlorotyrosine
Formation and significance
The enzyme myeloperoxidase (MPO) is secreted by neu-
trophils, monocytes, and some macrophages, and is a key
component of inflammatory response (47). It uses hydrogen
peroxide and chloride ions to generate hypochlorous acid
(HOCl) as a defense against microorganisms, but it can also
inflict oxidative damage on proteins and lipids (31). HOCl can
react with protein-bound Tyr, and this is the only known
source of 3-chlorotyrosine (3ClY) formation in humans,
making this modification a good fingerprint for oxidative
damage promoted by MPO (16, 31). HOCl can further chlo-
rinate 3ClY to form DiClY (42). In addition, MPO can generate
NO2 from nitrite or ONOO
- , which can generate 3NY, as
well as tyrosyl radicals, leading to DiY and other Tyr-derived
cross-links (26, 31).
3ClY has been found in many inflammatory disease states,
such as in synovial fluid from rheumatoid arthritis patients
(45). In addition, both MPO and its products, particularly
3ClY and 3NY, are known to be enriched in human athero-
sclerotic plaques and in plasma from patients with cardio-
vascular disease (5, 16, 47). Indeed, plasma MPO level has
been shown to be an effective predictor of major adverse
coronary events in patients presenting with chest pain to the
emergency department (5).
Chlorination of HDL may contribute to atherogenesis
Studies of specific 3ClY sites in proteins are scarce, but
there has been interest in characterizing the role of MPO in
the oxidative damage of high-density lipoprotein (HDL),
particularly its major protein component, apolipoprotein A-
I (apoAI). Figure 6 shows the locations of several important
oxidation sites. While there is agreement in the literature
that MPO selectively targets Tyr-192 (a highly conserved
residue) in lipid-free apoAI for both chlorination and ni-
tration, with lower levels observed at the other six Tyr
residues (34, 50), the functional impact of this specific
modification is controversial. There is agreement that MPO-
mediated modification, and specifically the 3ClY and 3NY
content of apoAI, correlates with loss of cholesterol efflux
activity mediated by ATP-binding cassette transporter A1
(ABCA1) (34, 49), and that both chlorinated and nitrated
apoAI are enriched in human plasma from patients with
cardiovascular disease and even more so in atheromas
isolated from such patients (49, 50). Shao et al. (34) further
demonstrated that the specific modification of Tyr-192 to
3ClY shows a strong linear correlation with the loss of
ABCA1-dependent cholesterol efflux activity. Additional,
contradictory findings are briefly described below, and for
recent related reviews from both groups actively research-
ing this subject, see Refs. 35 and 39.
In a series of studies, the groups of Heinecke and Oram
described roles for Tyr, Lys, and Met residues in the MPO-
mediated inactivation of apoAI cholesterol efflux activity via
ABCA1. While Tyr-192 was the major target for both chlori-
nation and nitration by MPO (and also nitration by ONOO - ),
the latter modification did not significantly affect the
FIG. 5. Lysosomal pathway to apoptosis mediated by the accumulation of aggregated proteins following metabolic
incorporation of DOPA. Figure based on information from Refs. 10 and 18.
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biological activity (34). Nearby Lys residues on the same face
of the amphipathic helix as Tyr, specifically in YXXK motifs,
regiospecifically directed Tyr chlorination via chloramine in-
termediates formed on the e-amino group of Lys (4, 36). Point
mutations designed to add or remove Met residues near target
Tyr residues showed their capacity to act as intramolecular
antioxidants to inhibit the chlorination (36), as also demon-
strated in a later study by Peng et al. (29).
Paradoxically, Shao et al. (36) presented evidence that Met
oxidation, along with Tyr-192 chlorination, was required to
impair cholesterol transport activity of apoAI. Mutation of
Tyr-192 to the more MPO-oxidation-resistant Phe (Y192F)
gave a functional apoAI that was protected slightly from
chlorination-dependent loss of activity. Following quantita-
tive oxidation of all three native Met residues to Met sulfoxide
by the MPO system, their complete conversion back to Met by
the methionine sulfoxide reductase enzyme PilB resulted in
partial recovery of activity. While neither of these strategies
led to full recovery on its own, the combination of the Y192F
mutation and PilB treatment almost completely restored the
activity to that of unmodified, wild-type apoAI, leading to the
conclusion that both Tyr-192 chlorination and Met oxidation
contribute to MPO-mediated functional impairment.
Toward an understanding of the mechanism underlying
impaired reverse cholesterol transport, Shao et al. (37) showed
that while both unmodified and nitrated apoAI were able to
compete with 125I-labeled apoAI for binding to ABCA1, the
MPO-treated protein could not. Furthermore, their data in-
dicated that the lipid-binding ability of the protein was not
compromised by MPO treatment. Since Tyr-192 and all three
oxidized Met are in or near hinge regions of apoAI (Fig. 5),
their modification may interfere with the rearrangement of its
hairpin loops that is required for interaction with ABCA1. The
resulting impairment of cholesterol removal from lipid-laden
macrophages or foam cells would promote formation of ath-
erosclerotic plaque (35).
Other researchers have also independently identified Tyr-
192 in apoAI as a major target for chlorination by MPO, but
their data has not supported a significant functional impact
for this particular modification in murine macrophages. Ra-
ther, their mutation of all seven Tyr residues to Phe conferred
no protective effect for cholesterol efflux activity following
MPO treatment of apoAI (30). On the other hand, mutation of
all four Trp residues to Phe did make apoAI resistant to MPO-
mediated oxidation, leading to the conclusion that mono- and
di-hydroxylated Trp is responsible for loss of apoAI’s
ABCA1-dependent cholesterol efflux activity (29).
Acknowledging these discrepancies, Shao et al. (36) suggest
that different cell culture models may behave differently, spe-
cifically proposing that since their ABCA1-transfected baby
hamster kidney cells express higher levels of ABCA1 than
murine macrophages, the modest protective effect of replacing
Tyr-192 with Phe is more easily detected. Furthermore, Shao
and Heinecke (35) point to structural changes in the Trp-free
mutant that may explain its resistance to MPO-mediated in-
activation, rather than the absence of oxidizable Trp. They
specifically cite the increase in a-helical content from 56% for
the wild-type to 71% in the Trp-free mutant (29, 35).
There are likely many factors that contribute to HDL dys-
function in atherosclerosis (see Ref. 39 for a useful discussion),
of which modification of Tyr and other amino acids is only
one. Even so, specific characterization of the residues in-
volved in oxidation-mediated protein damage may open new
diagnostic and therapeutic avenues, both through the use of
modified residues as biomarkers and the development of
oxidation-resistant forms of apoAI as more effective anti-
atherogenic agents for possible therapeutic use (35, 36, 38). In
particular, the specificity of 3ClY as a marker for MPO activity
and the link between MPO and disease progression may make
it an important diagnostic and/or therapeutic tool.
Conclusions
Tyr modification has been demonstrated to have important
consequences for protein function and structure in many
cases. In others, there is still an opportunity to learn what
impact these PTMs may have on particular proteins and what
role they may play. As the work of identifying, isolating, and
characterizing modified proteins under conditions relevant to
biological aging and age-related diseases continues, novel
insights and deeper understanding of physiological and
pathological processes can ultimately lead to improved di-
agnostic methods and therapeutic interventions for patients.
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Abbreviations Used
3ClY¼ 3-chlorotyrosine
3NY¼ 3-nitrotyrosine
ABCA1¼ATP-binding cassette transporter A1
AD¼Alzheimer’s disease
ALS¼ amyotrophic lateral sclerosis
apoAI¼ apolipoprotein A-I
DiClY¼ 3,5-dichlorotyrosine
DiY¼ 3,3¢-dityrosine
DOPA¼ 3,4-dihydroxyphenylalanine
DQ¼dopaquinone
EPO¼ eosinophil peroxidase
FeSOD¼ iron superoxide dismutase
GAPDH¼ glyceraldehyde-3-phosphate
dehydrogenase
HDL¼high-density lipoprotein
HOBr¼hypobromous acid
HOCl¼hypochlorous acid
HPLC¼high-performance liquid chromatography
HPLC-MS/MS¼high-performance liquid chromatography-
tandem mass spectrometry
MnSOD¼manganese superoxide dismutase
MPO¼myeloperoxidase
m-Tyr¼meta-tyrosine, 3-hydroxyphenylalanine
NO¼nitric oxide
NO2¼nitrogen dioxide
o-Tyr¼ ortho-tyrosine, 2-hydroxyphenylalanine
ONOO ¼peroxynitrite
PD¼Parkinson’s disease
PTM¼post-translational modification
ROS¼ reactive oxygen species
SDS-PAGE¼ sodium dodecyl sulfate polyacrylamide
gel electrophoresis
TPO¼ thyroid peroxidase
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